FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079581445> ?p ?o ?g. }

• W2079581445 endingPage "112" @default.
• W2079581445 startingPage "100" @default.
• W2079581445 abstract "Background The association of survival with characteristics of thrice-weekly hemodialysis (HD) treatment, including dose or duration of treatment, has not been completely elucidated, especially in different race and sex categories. Study Design We examined associations of time-averaged and quarterly varying (time-dependent) delivered HD dose and treatment time and 5-year (July 2001-June 2006) survival. Setting & Participants 88,153 thrice-weekly–treated HD patients from DaVita dialysis clinics. Predictors HD treatment dose (single-pool Kt/V) and treatment time. Outcomes & Other Measurements 5-Year mortality. Results Thrice-weekly treatment time < 3 hours (but ≥ 2.5 hours) per HD session compared with ≥ 3.5 hours (but < 5 hours) was associated with increased death risk independent of Kt/V dose. The greatest survival gain of higher HD dose was associated with a Kt/V approaching the 1.6-1.8 range, beyond which survival gain was minimal, nonexistent, or even tended to reverse in African American men and those with 4-5 hours of HD treatment. In non-Hispanic white women, Kt/V > 1.8 continued to show survival advantage trends, especially in time-dependent models. Limitations Our results may incorporate uncontrolled confounding. Achieved Kt/V may have different associations than targeted Kt/V. Conclusions HD treatment dose and time appear to have different associations with survival in different sex or race groups. Randomized controlled trials may be warranted to examine these associations across different racial and demographic groups. The association of survival with characteristics of thrice-weekly hemodialysis (HD) treatment, including dose or duration of treatment, has not been completely elucidated, especially in different race and sex categories. We examined associations of time-averaged and quarterly varying (time-dependent) delivered HD dose and treatment time and 5-year (July 2001-June 2006) survival. 88,153 thrice-weekly–treated HD patients from DaVita dialysis clinics. HD treatment dose (single-pool Kt/V) and treatment time. 5-Year mortality. Thrice-weekly treatment time < 3 hours (but ≥ 2.5 hours) per HD session compared with ≥ 3.5 hours (but < 5 hours) was associated with increased death risk independent of Kt/V dose. The greatest survival gain of higher HD dose was associated with a Kt/V approaching the 1.6-1.8 range, beyond which survival gain was minimal, nonexistent, or even tended to reverse in African American men and those with 4-5 hours of HD treatment. In non-Hispanic white women, Kt/V > 1.8 continued to show survival advantage trends, especially in time-dependent models. Our results may incorporate uncontrolled confounding. Achieved Kt/V may have different associations than targeted Kt/V. HD treatment dose and time appear to have different associations with survival in different sex or race groups. Randomized controlled trials may be warranted to examine these associations across different racial and demographic groups." @default.
• W2079581445 created "2016-06-24" @default.
• W2079581445 creator A5005273634 @default.
• W2079581445 creator A5015456552 @default.
• W2079581445 creator A5025116275 @default.
• W2079581445 creator A5047313234 @default.
• W2079581445 creator A5058979931 @default.
• W2079581445 creator A5061830161 @default.
• W2079581445 creator A5074587712 @default.
• W2079581445 creator A5084375517 @default.
• W2079581445 date "2010-01-01" @default.
• W2079581445 modified "2023-10-13" @default.
• W2079581445 title "Association of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex" @default.
• W2079581445 cites W1485491748 @default.
• W2079581445 cites W1965284757 @default.
• W2079581445 cites W1967555998 @default.
• W2079581445 cites W1969196500 @default.
• W2079581445 cites W1984721376 @default.
• W2079581445 cites W1987856637 @default.
• W2079581445 cites W1989169668 @default.
• W2079581445 cites W1991070614 @default.
• W2079581445 cites W1993518728 @default.
• W2079581445 cites W2002720021 @default.
• W2079581445 cites W2009730157 @default.
• W2079581445 cites W2013239569 @default.
• W2079581445 cites W2014334598 @default.
• W2079581445 cites W2017305383 @default.
• W2079581445 cites W2022751521 @default.
• W2079581445 cites W2024543272 @default.
• W2079581445 cites W2032655768 @default.
• W2079581445 cites W2035221187 @default.
• W2079581445 cites W2041203247 @default.
• W2079581445 cites W2049937445 @default.
• W2079581445 cites W2054361787 @default.
• W2079581445 cites W2057554304 @default.
• W2079581445 cites W2059510229 @default.
• W2079581445 cites W2066277984 @default.
• W2079581445 cites W2070309439 @default.
• W2079581445 cites W2075318106 @default.
• W2079581445 cites W2083530955 @default.
• W2079581445 cites W2085329362 @default.
• W2079581445 cites W2086572242 @default.
• W2079581445 cites W2086953287 @default.
• W2079581445 cites W2087724260 @default.
• W2079581445 cites W2096893986 @default.
• W2079581445 cites W2098787760 @default.
• W2079581445 cites W2099758743 @default.
• W2079581445 cites W2102324358 @default.
• W2079581445 cites W2105004826 @default.
• W2079581445 cites W2105642896 @default.
• W2079581445 cites W2116905163 @default.
• W2079581445 cites W2123493410 @default.
• W2079581445 cites W2123808226 @default.
• W2079581445 cites W2128372431 @default.
• W2079581445 cites W2130381721 @default.
• W2079581445 cites W2133154556 @default.
• W2079581445 cites W2137958137 @default.
• W2079581445 cites W2138222693 @default.
• W2079581445 cites W2139052411 @default.
• W2079581445 cites W2150153646 @default.
• W2079581445 cites W2150953623 @default.
• W2079581445 cites W2159877216 @default.
• W2079581445 cites W2165689184 @default.
• W2079581445 doi "https://doi.org/10.1053/j.ajkd.2009.08.007" @default.
• W2079581445 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2803335" @default.
• W2079581445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19853336" @default.
• W2079581445 hasPublicationYear "2010" @default.
• W2079581445 type Work @default.
• W2079581445 sameAs 2079581445 @default.
• W2079581445 citedByCount "110" @default.
• W2079581445 countsByYear W20795814452012 @default.
• W2079581445 countsByYear W20795814452013 @default.
• W2079581445 countsByYear W20795814452014 @default.
• W2079581445 countsByYear W20795814452015 @default.
• W2079581445 countsByYear W20795814452016 @default.
• W2079581445 countsByYear W20795814452017 @default.
• W2079581445 countsByYear W20795814452018 @default.
• W2079581445 countsByYear W20795814452019 @default.
• W2079581445 countsByYear W20795814452020 @default.
• W2079581445 countsByYear W20795814452021 @default.
• W2079581445 countsByYear W20795814452022 @default.
• W2079581445 crossrefType "journal-article" @default.
• W2079581445 hasAuthorship W2079581445A5005273634 @default.
• W2079581445 hasAuthorship W2079581445A5015456552 @default.
• W2079581445 hasAuthorship W2079581445A5025116275 @default.
• W2079581445 hasAuthorship W2079581445A5047313234 @default.
• W2079581445 hasAuthorship W2079581445A5058979931 @default.
• W2079581445 hasAuthorship W2079581445A5061830161 @default.
• W2079581445 hasAuthorship W2079581445A5074587712 @default.
• W2079581445 hasAuthorship W2079581445A5084375517 @default.
• W2079581445 hasBestOaLocation W20795814452 @default.
• W2079581445 hasConcept C10515644 @default.
• W2079581445 hasConcept C126322002 @default.
• W2079581445 hasConcept C144024400 @default.
• W2079581445 hasConcept C149923435 @default.
• W2079581445 hasConcept C168563851 @default.
• W2079581445 hasConcept C2549261 @default.
• W2079581445 hasConcept C2778063415 @default.

• next